STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] VERACYTE, INC. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Veracyte, Inc. furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The results are provided in a press release attached as Exhibit 99.1.

The company states this information, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act, and is not incorporated by reference unless specifically so stated.

Positive
  • None.
Negative
  • None.
FALSE000138410100013841012025-11-042025-11-04


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2025

VERACYTE, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-36156
20-5455398
(State or other jurisdiction of
incorporation)
Commission File Number
(IRS Employer Identification
No.)
6000 Shoreline Court, Suite 300, South San Francisco, California
94080
(Address of principal executive offices)
(Zip Code)

Registrant’s telephone number, including area code: (650) 243-6300
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
VCYT
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





Item 2.02.    Results of Operations and Financial Condition.

On November 4, 2025, Veracyte, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this report.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.


Item 9.01    Financial Statements and Exhibits.

(d) Exhibits.
Exhibit No.Description
99.1
Press release issued by Veracyte, Inc. dated November 4, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).





SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated:
November 4, 2025
VERACYTE, INC.
By:
/s/ Rebecca Chambers
Name:
Rebecca Chambers
Title:
Chief Financial Officer
Principal Financial Officer


FAQ

What did Veracyte (VCYT) announce in this 8-K?

Veracyte furnished a press release with financial results for the quarter ended September 30, 2025.

Where can I find the detailed results for Veracyte (VCYT)?

The detailed results are in Exhibit 99.1, the press release attached to the 8-K.

Is the information in the Veracyte 8-K considered filed or furnished?

It is furnished and not deemed “filed” under Section 18 of the Exchange Act.

What period do the results cover for Veracyte (VCYT)?

They cover the quarter ended September 30, 2025.

What exhibits are included with Veracyte’s 8-K?

The 8-K includes Exhibit 99.1 (press release) and Exhibit 104 (Cover Page Interactive Data File).

What is Veracyte’s trading symbol and exchange?

Veracyte trades under VCYT on The Nasdaq Stock Market LLC.
Veracyte

NASDAQ:VCYT

VCYT Rankings

VCYT Latest News

VCYT Latest SEC Filings

VCYT Stock Data

2.84B
78.26M
0.51%
109.51%
10.22%
Diagnostics & Research
Services-medical Laboratories
Link
United States
SOUTH SAN FRANCISCO